Dominant expression of CXCR3 is associated with induced expression of IP-10 at hapten-challenged sites of murine contact hypersensitivity:: a possible role for interferon-γ-producing CD8+ T cells in IP-10 expression

被引:33
作者
Tokuriki, A
Seo, N
Ito, T
Kumakiri, M
Takigawa, N
Tokura, Y
机构
[1] Hamamatsu Univ Sch Med, Dept Dermatol, Hamamatsu, Shizuoka 4313192, Japan
[2] Fukui Med Univ, Dept Dermatol, Matsuoka, Fukui 9101193, Japan
关键词
IP-10; CXCR3; chemokine; contact hypersensitivity; hapten;
D O I
10.1016/S0923-1811(01)00172-4
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Marine contact hypersensitivity is elicited as a consequence Of immunologic reactions triggered h skin-applied antigen, interactions among Langerhans cells. T cells. keratinocytes and mast cells. and a variety of chemokines generated by cellular interactions. In this study. we sensitized and challenged BALB c mice with hapten. dinitrofluorobenzene or picryl chloride. and examined the expressions of mRNA for chemokines and their receptors by reverse transcription-polymerase chain reaction in the skin of elicited earlobes. CXC chemokines. IP-10 and Mig, were transcribed 24-48 h after challenge. This vas associated with the expression of their agonistic receptor CXCR3. while mRNA for TARC and MDC, and their receptor CCR4 were not detected, Since CXCR3 and CCR4 are expressed preferentially on types 1 (Th1 Tc1) and 2 (Th2) T cells, respectively, the results suggested that the former type of T cells predominantly infiltrate at the elicited sites. Immune lymph node cells of the sensitized mice also expressed mRNA for CXCR3 but not CCR4 with concomitant transcription of interferon-gamma (IFN-gamma) but not interleukin-4 subsequent to challenge. The percentage of lymph node CD8(+) T cells as increased from 16%, in naive mice to 30-50%. in hapten-challenged mice. and in the immune lymph nodes. CD8(+) cells were the major source of IFN-gamma compared to CD4(+) cells. Since IFN-gamma is known to stimulate keratinocytes to produce IP-10 and Mig, it is suggested that these IFN-gamma-producing CD8(+) T cells enhance the production of these chemokines. thereby functioning as not only the effector cells but also the cytokine source to sustain the challenge reaction. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:234 / 241
页数:8
相关论文
共 33 条
[1]   Interferon-gamma inducible protein (IP-10) expression is mediated by CD8(+) T cells and is regulated by CD4(+) T cells during the elicitation of contact of hypersensitivity [J].
Abe, M ;
Kondo, T ;
Xu, H ;
Fairchild, RL .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1996, 107 (03) :360-366
[2]   IL-4 enhances keratinocyte expression of CXCR3 agonistic chemokines [J].
Albanesi, C ;
Scarponi, C ;
Sebastiani, S ;
Cavani, A ;
Federici, M ;
De Pità, O ;
Puddu, P ;
Girolomoni, G .
JOURNAL OF IMMUNOLOGY, 2000, 165 (03) :1395-1402
[3]  
Andrew DP, 1998, J IMMUNOL, V161, P5027
[4]   KERATINOCYTES AS INITIATORS OF INFLAMMATION [J].
BARKER, JNWN ;
MITRA, RS ;
GRIFFITHS, CEM ;
DIXIT, VM ;
NICKOLOFF, BJ .
LANCET, 1991, 337 (8735) :211-214
[5]  
Biedermann T, 2001, EUR J IMMUNOL, V31, P1582, DOI 10.1002/1521-4141(200105)31:5<1582::AID-IMMU1582>3.0.CO
[6]  
2-M
[7]   Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s [J].
Bonecchi, R ;
Bianchi, G ;
Bordignon, PP ;
D'Ambrosio, D ;
Lang, R ;
Borsatti, A ;
Sozzani, S ;
Allavena, P ;
Gray, PA ;
Mantovani, A ;
Sinigaglia, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (01) :129-134
[8]   Chemokine IP-10 expression in cultured human keratinocytes [J].
Boorsma, DM ;
Flier, J ;
Sampat, S ;
Ottevanger, C ;
de Haan, P ;
Hooft, L ;
Willemze, R ;
Tensen, CP ;
Stoof, TJ .
ARCHIVES OF DERMATOLOGICAL RESEARCH, 1998, 290 (06) :335-341
[9]   HUMAN GROWTH-FACTOR (HUGRO), INTERLEUKIN-8 (IL-8) AND INTERFERON-GAMMA-INDUCIBLE PROTEIN (GAMMA-I-IP-10) GENE-EXPRESSION IN CULTURED NORMAL HUMAN KERATINOCYTES [J].
BOORSMA, DM ;
DEHAAN, P ;
WILLEMZE, R ;
STOOF, TJ .
ARCHIVES OF DERMATOLOGICAL RESEARCH, 1994, 286 (08) :471-475
[10]  
D'Ambrosio D, 1998, J IMMUNOL, V161, P5111